story of the week
Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer: Updated Results From DESTINY-Breast03
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Lancet 2022 Dec 06;[EPub Ahead of Print], SA Hurvitz, R Hegg, WP Chung, SA Im, W Jacot, V Ganju, JWY Chiu, B Xu, E Hamilton, S Madhusudan, H Iwata, S Altintas, JW Henning, G Curigliano, JM Perez-Garcia, SB Kim, V Petry, CS Huang, W Li, JS Frenel, S Antolin, W Yeo, G Bianchini, S Loi, J Tsurutani, A Egorov, Y Liu, J Cathcart, S Ashfaque, J CortésFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.